China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into a cooperation framework agreement with Wuxi Gaofa Investment Development Group Co., Ltd to establish a joint venture (JV). The JV will focus on the research, development, manufacturing, and sale of golidocitinib and DZD8586, which are treatments for autoimmune diseases including atopic dermatitis, vitiligo, chronic spontaneous urticaria, and alopecia areata.
Investment and Intellectual Property Rights Transfer
Under the terms of the agreement, Dizal and Gaofa will invest RMB 700 million (USD 98 million) and RMB 100 million (USD 14 million), respectively, to secure 87.50% and 12.50% stakes in the JV. Following the JV’s establishment, Dizal will transfer all basic intellectual property (IP) rights related to golidocitinib and DZD8586 for the development of the mentioned auto-immune diseases, along with technical training and guidance support. In return, the JV will pay Dizal RMB 700 million (USD 98 million) for the IP rights.
Clinical Progress of Golidocitinib and DZD8586
Golidocitinib, a JAK1 inhibitor, is currently in clinical studies for the treatment of peripheral T-cell lymphoma (PTCL), for which Dizal has filed for marketing approval in China. DZD8586, a non-covalent LYN/BTK inhibitor capable of penetrating the blood-brain barrier, has demonstrated favorable pharmacokinetic (PK) characteristics, safety, and anti-tumor activity in preclinical and clinical studies for B-cell non-Hodgkin’s lymphoma (B-NHL).- Flcube.com
